dotMD.com
✓ Translated by DotMD AI Clinical Council Source: The journal of sexual medicine • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #20345732
Plain-English Research Story • 8th-Grade Reading Level

Can This Approach Help? Inside the Latest Research on Real-world benefits and safety of testosterone undecanoate (Nebido(®)) in

In this prospective multicenter study, TU was effective, safe, and tolerable until 24 weeks in Korean TDS patients.

Original Paper Title: “The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study” (The journal of sexual medicine, 2010-06-15)

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: In this prospective multicenter study, TU was effective, safe, and tolerable until 24 weeks in Korean TDS patients.
  • Who Was Studied: Randomized Controlled Trial published in The journal of sexual medicine following multiple clinical patient groups.
  • Strength of the Evidence: Earned a 82/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

Long-acting injectable testosterone undecanoate (TU, Nebido(®)), a new parenteral testosterone preparation, has recently been introduced to avoid frequent injections of the conventional injectable esters. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in The journal of sexual medicine conducted a randomized controlled trial evaluating multiple clinical patient groups. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

In this prospective multicenter study, TU was effective, safe, and tolerable until 24 weeks in Korean TDS patients. Further well-controlled, long-term study should follow. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in The journal of sexual medicine (2010-06-15) • Study Design: Randomized Controlled Trial • Participants: Pooled Clinical Review • Biostatistical Rigor Score: 82/100. Primary Takeaway: In this prospective multicenter study, TU was effective, safe, and tolerable until 24 weeks in Korean TDS patients.

Study Limitations & Caveats Before You Act

While this randomized controlled trial scored 82/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study”
Published in The journal of sexual medicine (2010-06-15) • PMID/ID: 20345732
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 20345732: Can This Approach Help? Inside the Latest Research on Real-world benefits and safety of testosterone undecanoate (Nebido(®)) in

3 of 3 Free Questions Remaining